Supplementary Table S3. PRODIGE13 Patients characteristics

Variable	Overall N = 529[1]	No relapse (R0) N = 449[1]	Relapse (R1) N = 80[1]	p-value[2]
		Relapse status		
Age (years)	68 (60, 75)	68 (61, 75)	69 (60, 75)	0.82
Sex				0.43
Female	213 (40%)	184 (41%)	29 (36%)	
Male	316 (60%)	265 (59%)	51 (64%)	
MMR status				0.004
pMMR	373 (81%)	306 (78%)	67 (93%)	
dMMR	90 (19%)	85 (22%)	5 (6.9%)	
pT stage				0.053
pT1	1 (0.2%)	1 (0.2%)	0 (0%)	
pT2	20 (3.8%)	18 (4.0%)	2 (2.5%)	
pT3	420 (80%)	363 (82%)	57 (71%)	
pT4	84 (16%)	63 (14%)	21 (26%)	
Histologic grade				>0.99
G1-2	477 (96%)	405 (96%)	72 (96%)	
G3-4	19 (3.8%)	16 (3.8%)	3 (4.0%)	
Risk group				0.007
Low Risk (pT1-3)	441 (84%)	382 (86%)	59 (74%)	
High Risk (pT4)	84 (16%)	63 (14%)	21 (26%)	
Bowel obstruction or perforation	91 (17%)	64 (14%)	27 (34%)	<0.001
Tumor location				0.27
Distal	261 (49%)	221 (49%)	40 (50%)	
Proximal	235 (44%)	203 (45%)	32 (40%)	
Rectal	33 (6.2%)	25 (5.6%)	8 (10%)	
Adjuvant chemotherapy				0.012
Chemotherapy	156 (29%)	123 (27%)	33 (41%)	
No chemotherapy	373 (71%)	326 (73%)	47 (59%)	

[1]Median (IQR) or Frequency (%)

[2]Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test